RAS突变型转移性结直肠癌的精准治疗  

Precision Therapy of Metastatic Colorectal Cancer with RAS Mutation

作　　者：邹佳运 杨天瑶 王颖[1] ZOU Jiayun;YANG Tianyao;WANG Ying(Department of Oncology,Shengjing Hospital of China Medical University,Shenyang110004,China;Teaching and Research Room of Environmental Health,Academy of PublicHealth,China Medical University,Shenyang 110122,China)

机构地区：[1]中国医科大学附属盛京医院肿瘤科,沈阳110004 [2]中国医科大学公共卫生学院环境卫生学教研室,沈阳110122

出　　处：《肿瘤防治研究》2021年第8期820-824,共5页Cancer Research on Prevention and Treatment

基　　金：辽宁省自然科学基金指导计划(20180550878)。

摘　　要：转移性结直肠癌(mCRC)是一种异质性疾病,临床表现和分子分型差异大。目前,mCRC在治疗前需要常规行大鼠肉瘤病毒(RAS)基因检测。RAS突变状态与患者预后显著相关并能预测抗表皮生长因子受体(EGFR)治疗的疗效,然而仍缺乏针对RAS靶点的特异性治疗手段。既往研究表明直接抑制RAS蛋白带来的临床获益非常有限,最近报道了一种能够直接抑制KRAS G12C的有前景的药物—AMG-510,但还需要大样本研究进一步证实。近年来,通过抑制RAS基因相关效应器间接抑制RAS的表达、多靶点联合治疗及免疫治疗等均取得重要进展,有望成为针对RAS靶点的有效治疗手段。本文针对RAS突变型mCRC的精准治疗进行总结。Metastatic colorectal cancer(mCRC)is a clinical and molecular heterogeneous disease.Currently,for mCRC,extended rat sarcoma(RAS)testing is recommended in routine clinical practice before any treatment.RAS mutational status is significantly associated with the outcome of patients and strongly predictive for anti-EGFR-targeted therapy.However,specific treatments for RAS target are not yet available.Previous studies have shown that direct inhibition of RAS proteins has limited clinical benefits.Recently,a promising drug,AMG-510,which can directly inhibit KRAS G12C has been reported;however,it needs further confirmation.In the past few years,important advances have also been made in approaches designed to indirectly target RAS by inhibiting RAS effectors,multi-target combination strategies and immunotherapy.They are expected to be effective treatments for RAS target.This article summarizes the precision treatment of RAS-mutant mCRC.

关 键 词：结直肠癌 RAS基因突变 精准治疗 

分 类 号：R735.3[医药卫生—肿瘤]